In 1967, the U.S. surgeon general declared it was time “to close the book on infectious diseases.” With the introduction of new classes of powerful antibiotics, cholera, influenza, typhoid, whooping cough and other communicable diseases were brought under control. It certainly seemed as if bacterial infections, at least, were becoming a thing of the past.
Bacteria, however, have proven to be remarkably adept at surviving. Bacteria have developed a number of mechanisms to evade antibiotic agents. One of the most common is the production of enzymes such as the β-lactamases that can destroy the very structure of β-lactam antibiotics, rendering them ineffective. It is estimated that β-lactamase-producing bacteria are now resistant to 50% of prescription antibiotics including penicillin.
Without these first lines of defense against bacterial infections, infections will be become harder to treat, healthcare costs will continue to rise and, according to the director general of the World Health Organization, we could be facing “the end of modern medicine as we know it.”
At Gordian Biotechnologies, we are committed to developing solutions to these global healthcare challenges.
I founded Gordian with the sole objective of developing the next generation of β-lactamase inhibitors. Working with our partners at USF and USCSF, we are advancing a new first-in-class family of β-lactamase inhibitors that has been shown in preliminary studies to be effective against all known classes of β-lactamases. If we are successful in bringing these candidates forward through clinical trials and to the market, we have the potential to restore the potency of penicillin and other β‑lactam antibiotics, which are so crucial to the practice of modern medicine.
These are exciting times and I look forward to keeping you apprised on our progress.
-Tony Brazzale, CEO